ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of inflammatory and renal diseases, is pleased
to announce that world renowned inflammasome researchers and
inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100 have
published a scientific paper in the peer-reviewed journal,
Alzheimer’s & Dementia: Translational Research & Clinical
Interventions.
In the paper titled, “Association of region-specific hippocampal
reduction of neurogranin with inflammasome proteins in postmortem
brains of Alzheimer’s disease,” the researchers demonstrated that
loss of plasticity and neuronal scaffolding proteins, part of the
neurodegenerative process leading to memory and learning deficits
in AD, is associated with recruitment of ASC molecules and
formation of inflammasome complexes in both neurons and
microglia.
“Our data emphasize that the synapse may be more vulnerable when
the inflammatory machinery is activated, supporting the potential
role of targeting ASC specks during the progression of AD
pathology,” said Dr. Regina T. Vontell, Research Assistant
Professor and Associate Director, Brain Endowment Bank at the
University of Miami Miller School of Medicine.
“Our earlier data demonstrated that ASC correlated with Aβ and
p-tau in postmortem cases with AD pathology, and that neurons in
areas of the brain that are particularly susceptible to death in
the early and intermediate stages of the disease process could be
identified through imaging studies with Inflammasome ASC inhibitor
IC 100. This further supports the therapeutic potential of
targeting ASC in patients with AD,” stated Dr. Robert W. Keane,
Professor, Physiology and Biophysics, Neurological Surgery and
Microbiology, and Immunology at the University of Miami Miller
School of Medicine, and a member of ZyVersa’s Inflammatory Disease
Scientific Advisory Board.
Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and
President, commented, “The research published in Alzheimer’s &
Dementia: Translational Research & Clinical Interventions
reinforces the therapeutic potential of ZyVersa’s Inflammasome ASC
Inhibitor IC 100 in neurological diseases. Preclinical studies have
demonstrated reduced inflammatory activity and/or improved outcomes
in multiple sclerosis, age-related inflammation, spinal cord
injury, and two different models of brain injury.”
To review the publication, Click Here.
About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that
inhibits the inflammasome adaptor protein ASC. IC 100 was designed
to attenuate both initiation and perpetuation of the inflammatory
response. It does so by binding to a specific region of the ASC
component of multiple types of inflammasomes, including NLRP1,
NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to
ASC monomers, inhibiting inflammasome formation, thereby blocking
activation of IL-1β early in the inflammatory cascade. IC 100 also
binds to ASC in ASC Specks, both intracellularly and
extracellularly, further blocking activation of IL-1β and the
perpetuation of the inflammatory response that is pathogenic in
inflammatory diseases. Because active cytokines amplify adaptive
immunity through various mechanisms, IC 100, by attenuating
cytokine activation, also attenuates the adaptive immune
response.
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs for patients with
renal and inflammatory diseases who have significant unmet medical
needs. The Company is currently advancing a therapeutic development
pipeline with multiple programs built around its two proprietary
technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment
of kidney diseases, and Inflammasome ASC Inhibitor IC 100,
targeting damaging inflammation associated with numerous CNS and
other inflammatory diseases. For more information, please visit
www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate and IR Contact:Karen CashmereChief
Commercial
Officerkcashmere@zyversa.com786-251-9641
Media ContactsTiberend Strategic
Advisors, Inc.Casey
McDonaldcmcdonald@tiberend.com646-577-8520
Dave Schemeliadschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024